Fig. 1
From: Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment
ILC2 increases and NKG2D expression in COVID-19 patients. a Lung cell numbers (total ILCs, ILC2s, and eosinophils) and the frequencies of IL-5+ ILC2s in WT animals treated intranasally with SARS-CoV-2 PLpro vs those in untreated animals. b Percentages of total ILCs and ILC subsets in PBMCs in HDs vs those in COVID-19 patients and serum cytokine levels in HDs vs COVID-19 patients. c Phenotyping of ILC2s in PBMCs of HDs and mild and severe COVID-19 patients. Percentages of positive ILC2s and the mean fluorescence intensity (MFI) of NKG2D, CD25, KLRG1, and PD-1 are shown. d Serum levels of IL-18 in HDs vs those in COVID-19 patients (upper part) and NKG2D expression and the MFI in HD PBMCs after 48 h of in vitro cytokine stimulation with hrIL-18, hrIL-33 or both vs those in unstimulated cells. e Clinical characteristics of severely ill COVID-19 patients classified as NKGD2hi and NKGD2low based on the median expression of NKG2D on ILC2s in the total patient cohort
